Learn More
Germaine™ Laboratories SpeedySwab™ COVID-19/FLU AB Rapid Test
Description
- Lateral flow immunochromatographic assay intended for in-vitro rapid, simultaneous qualitative detection and differentiation of influenza A and B nucleoprotein antigens and SARS CoV-2 nucleocapsid antigen
- Sample directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 within the first five days of symptom onset when tested at least twice over three days with at least 48 hours between tests
- This test is FDA/EUA authorized for use at the Point of Care, i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
Specifications
Specifications
| CE Marker | No |
| Clia Complexity | Waived (EUA) |
| Detectable Analytes | Influenza A and B, COVID-19/2019-nCOV |
| Detection Method | Simultaneous Qualitative Detection |
| DoA Calibrators | No |
| Format | Kit |
| Sample Type | Single Nasal Swab Sample |
| Sensitivity | COVID Clinical Sensitivity: 92.6%;, FLU-A Clinical Sensitivity: 82.9%, FLU-B Clinical Sensitivity: 90.0%, Refer to the Package Insert for additional performance claims |
| Type | Rapid Test |
| Disposable | Single-use |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.